vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and WESTPORT FUEL SYSTEMS INC. (WPRT). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $12.5M, roughly 1.6× WESTPORT FUEL SYSTEMS INC.). Pulmonx Corp runs the higher net margin — -66.3% vs -274.8%, a 208.5% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -11.4%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

LUNG vs WPRT — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.6× larger
LUNG
$20.6M
$12.5M
WPRT
Growing faster (revenue YoY)
LUNG
LUNG
+2.8% gap
LUNG
-8.7%
-11.4%
WPRT
Higher net margin
LUNG
LUNG
208.5% more per $
LUNG
-66.3%
-274.8%
WPRT

Income Statement — Q1 FY2026 vs Q2 FY2025

Metric
LUNG
LUNG
WPRT
WPRT
Revenue
$20.6M
$12.5M
Net Profit
$-13.7M
$-34.3M
Gross Margin
77.9%
6.7%
Operating Margin
-40.9%
-8.1%
Net Margin
-66.3%
-274.8%
Revenue YoY
-8.7%
-11.4%
Net Profit YoY
5.5%
-690.4%
EPS (diluted)
$-0.33
$-1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
WPRT
WPRT
Q1 26
$20.6M
Q4 25
$22.6M
Q3 25
$21.5M
Q2 25
$23.9M
$12.5M
Q1 25
$22.5M
Q4 24
$23.8M
Q3 24
$20.4M
$4.9M
Q2 24
$20.8M
$14.1M
Net Profit
LUNG
LUNG
WPRT
WPRT
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$-14.0M
Q2 25
$-15.2M
$-34.3M
Q1 25
$-14.4M
Q4 24
$-13.2M
Q3 24
$-14.1M
$-3.9M
Q2 24
$-15.3M
$5.8M
Gross Margin
LUNG
LUNG
WPRT
WPRT
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
6.7%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
13.6%
Q2 24
73.7%
16.7%
Operating Margin
LUNG
LUNG
WPRT
WPRT
Q1 26
-40.9%
Q4 25
-43.8%
Q3 25
-66.9%
Q2 25
-62.0%
-8.1%
Q1 25
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
-43.9%
Q2 24
-75.2%
-54.9%
Net Margin
LUNG
LUNG
WPRT
WPRT
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
-64.9%
Q2 25
-63.6%
-274.8%
Q1 25
-64.1%
Q4 24
-55.4%
Q3 24
-69.4%
-79.3%
Q2 24
-73.7%
41.2%
EPS (diluted)
LUNG
LUNG
WPRT
WPRT
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$-0.34
Q2 25
$-0.38
$-1.98
Q1 25
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
$-0.22
Q2 24
$-0.39
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
WPRT
WPRT
Cash + ST InvestmentsLiquidity on hand
$61.6M
$6.1M
Total DebtLower is stronger
$37.3M
$977.0K
Stockholders' EquityBook value
$45.8M
$108.9M
Total Assets
$120.0M
$272.1M
Debt / EquityLower = less leverage
0.82×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
WPRT
WPRT
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
$6.1M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
LUNG
LUNG
WPRT
WPRT
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
$977.0K
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
LUNG
LUNG
WPRT
WPRT
Q1 26
$45.8M
Q4 25
$54.1M
Q3 25
$60.0M
Q2 25
$69.1M
$108.9M
Q1 25
$77.7M
Q4 24
$85.8M
Q3 24
$93.9M
$149.3M
Q2 24
$101.2M
$151.5M
Total Assets
LUNG
LUNG
WPRT
WPRT
Q1 26
$120.0M
Q4 25
$129.3M
Q3 25
$138.3M
Q2 25
$147.2M
$272.1M
Q1 25
$150.7M
Q4 24
$162.8M
Q3 24
$167.4M
Q2 24
$172.6M
Debt / Equity
LUNG
LUNG
WPRT
WPRT
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
0.01×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
WPRT
WPRT
Operating Cash FlowLast quarter
$-5.6M
Free Cash FlowOCF − Capex
$-6.4M
FCF MarginFCF / Revenue
-51.6%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
WPRT
WPRT
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.2M
Q2 25
$-3.9M
$-5.6M
Q1 25
$-13.2M
Q4 24
$-6.7M
Q3 24
$-7.2M
$-11.7M
Q2 24
$-5.8M
$1.5M
Free Cash Flow
LUNG
LUNG
WPRT
WPRT
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.3M
Q2 25
$-4.0M
$-6.4M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
$-11.9M
Q2 24
$-6.2M
$262.0K
FCF Margin
LUNG
LUNG
WPRT
WPRT
Q1 26
Q4 25
-31.4%
Q3 25
-38.4%
Q2 25
-16.6%
-51.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
-243.4%
Q2 24
-30.0%
1.9%
Capex Intensity
LUNG
LUNG
WPRT
WPRT
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.2%
6.6%
Q1 25
1.3%
Q4 24
0.5%
Q3 24
2.0%
3.8%
Q2 24
2.3%
8.9%
Cash Conversion
LUNG
LUNG
WPRT
WPRT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons